The Latest

Dolutegravir More Effective Than Efavirenz at Achieving Viral Suppression During Late-Term Pregnancy, New Study Shows

Unlike some previous studies that focused on early pregnancy, this study showed no associated congenital disabilities with either drug.

By Sony Salzman

Triumeq Virologically Superior to Boosted-Atazanavir Regimen in Women's Trial

A fixed-dose combination of dolutegravir plus abacavir/lamivudine proved virologically superior to once-daily ritonavir-boosted atazanavir plus tenofovir/emtricitabine, in a large study of women with HIV.

By Mark Mascolini

Switching to Single-Pill Regimen Controls HIV as Well as Other Standard Treatment

New data show equal control of HIV levels when switching from a standard multi-pill regimen to the single-tablet regimen of Triumeq.

By Project Inform

Switching to Abacavir/Dolutegravir/Lamivudine (Triumeq) Maintains Undetectable Viral Load

Paul Sax, M.D., recaps an important study presented at ICAAC 2015, which highlighted 24-week results for patients switching to abacavir/dolutegravir/lamivudine (Triumeq).

By Paul E. Sax, M.D. for NEJM Journal Watch